^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ELI-011

    i
    Other names: ELI-011, AMP-CD19, CD19 CAR-T AMPlifier
    Associations

    News

    Trials
    Company:
    Elicio Therap, Moffitt Cancer Center
    Drug class:
    CD19-targeted CAR-T immunotherapy, Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    over2years
    Amphiphile-peptide boosting with FMC63-binding surrogate peptide mimotopes induces activation and potent effector function in CAR-T cells targeting CD19 (SITC 2021)
    In vitro, human dendritic cells (DCs) were preconditioned with AMP-CD19 or soluble peptides and cocultured with autologous T cells engineered to express CD19 CARs (FMC63-28z and FMC63-41BBz)...These AMP-peptides effectively accumulate in LN and boost CAR-T activation and expansion in vivo. This platform can potentially be utilized as a mechanism to expand and functionally enhance CAR-T cells in vivo for blood and solid tumors.
    CAR T-Cell Therapy • IO biomarker
    |
    CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • LAMP1 (Lysosomal Associated Membrane Protein 1)
    |
    CD19 expression
    |
    ELI-011